Restless legs syndrome in end-stage renal disease

Gigli, Gian Luigi; Adorati, M.; Dolso, Pierluigi; Piani, Antonella; Valente, Mariarosaria; Brotini, Stefania; Budai, Riccardo

doi:10.1016/j.sleep.2004.01.014

Cited by 202 publications

(116 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[11,19,20]. According to the IRLSSG rating scale, severity was classified as mild (<11 on the IRLSSG rating scale), moderate (11)(12)(13)(14)(15)(16)(17)(18)(19)(20), severe (21)(22)(23)(24)(25)(26)(27)(28)(29)(30), and very severe (31)(32)(33)(34)(35)(36)(37)(38)(39)(40) [21]. The Page 6 of 35 prevalence of RLS found in that study was 26.6% (154/579).…”

Section: Methodsmentioning

confidence: 95%

See 1 more Smart Citation

Restless legs syndrome does not affect 3-year mortality in hemodialysis patients

et al. 2015

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Original Highlights of the studyWe evaluated the relationship of RLS and mortality in chronic hemodialysis patients For the diagnosis of RLS we implemented standard methodology, i.e. the essential clinical criteria of the International RLS Study Group. This is the first time this issue is investigated in an epidemiological survey in Greece.In contrast to previous reports the diagnosis of RLS does not influence the 3-year mortality in HD patients. ABSTRACTObjective: In chronic hemodialysis (HD) patients, the prevalence of restless legs syndrome (RLS) is significantly higher than in the general population. Uremic RLS has been related to an enhanced mortality of HD patients. In the general population, however, studies of this association have yielded inconsistent results. The aim of the present study was to re-evaluate the relationship of RLS and mortality in HD patients. Methods:We recorded the 3-year mortality rate in a population of 579 HD patients after assessment for RLS symptoms. In addition we analyzed the 5-year mortality rate after end-stage renal disease onset (i.e., commencement of HD). This HD patient population has been previously included in a cross-sectional survey of RLS prevalence in which RLS diagnosis was based on the essential clinical criteria of the International RLS Study Group. Mortality data were acquired from the national endstage renal disease registry. Survival probability was calculated by means of the Kaplan-Meier method and analyzed by the log-rank (Mantel-Cox) test. For multivariate survival analysis, we implemented a proportional hazards regression Conclusion: Diagnosis of RLS according to the essential clinical criteria of theInternational RLS Study Group does not seem to influence the 3-year mortality in HD patients. Our findings are in contrast to those in some previous reports, and reinforce the need for further studies of RLS and mortality in HD patients.

show abstract

Section: Methodsmentioning

confidence: 95%

“…Publication bias may be another reason for this contradiction. Survival studies, all positive, seem to be very scarce [12,13,15] among epidemiological surveys on RLS in HD patients [11,14,[27][28][29][30][31][32][33][34][35][36].…”

Section: Page 12 Of 35mentioning

confidence: 99%

Restless legs syndrome does not affect 3-year mortality in hemodialysis patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…There is a strong relationship between insomnia and depression, as insomnia is a symptom of depression and also a risk factor to deteriorate depression (9). There are reports on the correlation between RLS and mental health, depression, decreased quality of life, and increased mortality among patient underwent transplantation or undergoing hemodialysis (1,(10)(11)(12)(13)(14). RLS is one of the most powerful causes of insomnia in chronic kidney diseases, however, sleep disorder cause depression (11,15,16).…”

Section: Introductionmentioning

confidence: 99%

Restless Leg Syndrome, Insomnia, and Depression in Hemodialysis Patients: Three Sides of a Triangle?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The prevalence is almost 40 % in those with associated polyneuropathy [40]. Definitive treatment of end-stage renal failure associated RLS is kidney transplant [41,42].…”

Section: Treatment Of Secondary Rlsmentioning

confidence: 99%

Treatment of Restless Legs Syndrome

Comella¹

2014

Neurotherapeutics

View full text Add to dashboard Cite

Restless legs syndrome (RLS) is a common disorder diagnosed by the clinical characteristics of restlessness in the legs associated often with abnormal sensations that start at rest and are improved by activity, occurring with a diurnal pattern of worsened symptoms at night and improvement in the morning. RLS is the cause of impaired quality of life in those more severely afflicted. Treatment of RLS has undergone considerable change over the last few years. Several classes of medications have demonstrated efficacy, including the dopaminergic agents and the alpha-2-delta ligands. Levodopa was the first dopaminergic agent found to be successful. However, chronic use of levodopa is frequently associated with augmentation that is defined as an earlier occurrence of symptoms frequently associated with worsening severity and sometimes spread to other body areas. The direct dopamine agonists, including ropinirole, pramipexole, and rotigotine patch, are also effective, although side effects, including daytime sleepiness, impulse control disorders, and augmentation, may limit usefulness. The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur. Other agents, including the opioids and clonazepam do not have sufficient evidence to recommend them as treatment for RLS, although in an individual patient, they may provide benefit.

show abstract

Restless legs syndrome in end-stage renal disease

Cited by 202 publications

References 24 publications

Restless legs syndrome does not affect 3-year mortality in hemodialysis patients

Restless legs syndrome does not affect 3-year mortality in hemodialysis patients

Restless Leg Syndrome, Insomnia, and Depression in Hemodialysis Patients: Three Sides of a Triangle?

Treatment of Restless Legs Syndrome

Contact Info

Product

Resources

About